PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST.
The presentation will be accessible via a live webcast. The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
Investor Relations: Andrew Senn This email address is being protected from spambots. You need JavaScript enabled to view it. 763.951.8312 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 214.618.4216 |
Last Trade: | US$107.87 |
Daily Change: | 0.49 0.46 |
Daily Volume: | 159,200 |
Market Cap: | US$3.780B |
July 24, 2025 July 10, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load